Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
Venturini M, Michelotti A, Papaldo P, Del Mastro L, Bergaglio M, Lionetto R, Lunardi G, Sguotti C, Frevola L, Donati S, Rosso R, Cognetti F. Venturini M, et al. Among authors: lionetto r. Ann Oncol. 2001 Aug;12(8):1097-106. doi: 10.1023/a:1011663821703. Ann Oncol. 2001. PMID: 11583191 Free article. Clinical Trial.
Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
Venturini M, Del Mastro L, Testore F, Danova M, Garrone O, Lanfranco C, Latini F, Sertoli MR, Lionetto R, Queirolo P, Ardizzoni A, Rosso R. Venturini M, et al. Among authors: lionetto r. Cancer Chemother Pharmacol. 1996;38(6):487-94. doi: 10.1007/s002800050516. Cancer Chemother Pharmacol. 1996. PMID: 8823488
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, Tibaldi C, Molea N, Bellina RC, Pronzato P, Cyrus P, Vinke J, Testore F, Guelfi M, Lionetto R, Bruzzi P, Conte PF, Rosso R. Venturini M, et al. Among authors: lionetto r. J Clin Oncol. 1996 Dec;14(12):3112-20. doi: 10.1200/JCO.1996.14.12.3112. J Clin Oncol. 1996. PMID: 8955656 Clinical Trial.
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
Del Mastro L, Venturini M, Lionetto R, Carnino F, Guarneri D, Gallo L, Contu A, Pronzato P, Vesentini L, Bergaglio M, Comis S, Rosso R. Del Mastro L, et al. Among authors: lionetto r. J Clin Oncol. 2001 Apr 15;19(8):2213-21. doi: 10.1200/JCO.2001.19.8.2213. J Clin Oncol. 2001. PMID: 11304774 Clinical Trial.
Phase II study of lonidamine in metastatic breast cancer.
Pronzato P, Amoroso D, Bertelli G, Conte PF, Cusimano MP, Ciottoli GB, Gulisano M, Lionetto R, Rosso R. Pronzato P, et al. Among authors: lionetto r. Br J Cancer. 1989 Feb;59(2):251-3. doi: 10.1038/bjc.1989.51. Br J Cancer. 1989. PMID: 2930690 Free PMC article.
57 results